Dr. Luke Nordquist on Radium-223 Retreatment

Video

Luke Nordquist, MD, FACP, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a multicenter, prospective study of radium-223 retreatment in metastatic castration-resistant prostate cancer (mCRPC).

Luke Nordquist, MD, FACP, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a multicenter, prospective study of radium-223 retreatment in metastatic castration-resistant prostate cancer (mCRPC).

There were many questions that remained unanswered after the ALSYMPCA study, which led to the approval of radium-223, said Nordquist. One area where uncertainty remains is proper dosing. While this drug is approved at 50 kBq/kg monthly for 6 months in mCRPC, a higher dose may have more benefit.

To investigate this, a study was conduced with 44 patients who had mCRPC. The patients received up to an additional 6 doses of radium-223 after the original 6. The primary endpoint of the study was safety, but there were exploratory endpoints with radiographic progression and progression-free survival looking at PSA. In terms of safety, there was no marked differences compared with the safety of the ALSYMPCA trial. There was not a difference in the hematologic toxicity with the additional 6 doses, and there were no grade 4/5 hematologic toxicities reported, said Nordquist.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD